Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Issues Final Guidance on Developing GnRH Analogues for Advanced Prostate Cancer

  • Post author:PacConAdmin
  • Post published:May 26, 2022
  • Post category:Drug Industry Daily

In an effort to get more gonadotropin-releasing hormone (GnRH) analogues to market for advanced prostate cancer patients, the FDA has published final guidance with recommendations spanning the full spectrum of…

Continue ReadingFDA Issues Final Guidance on Developing GnRH Analogues for Advanced Prostate Cancer

Surging Oncology Research Yields Big Approval Dividends and Lucrative Payoffs, Study Says

  • Post author:PacConAdmin
  • Post published:May 26, 2022
  • Post category:Drug Industry Daily

Oncology research and drug development continue to surge globally, with 159 new medications launched since 2012 — and a record 30 of those in 2021 — according to the life…

Continue ReadingSurging Oncology Research Yields Big Approval Dividends and Lucrative Payoffs, Study Says

EMA Publishes Revised Guideline on Evaluating Antibacterial Drugs

  • Post author:PacConAdmin
  • Post published:May 25, 2022
  • Post category:Drug Industry Daily

To help support a global approach to developing new drugs that address antimicrobial resistance (AMR), the European Medicines Agency (EMA) has published a final guideline aimed at aligning data requirements…

Continue ReadingEMA Publishes Revised Guideline on Evaluating Antibacterial Drugs

FDA Issues ‘Small Entity’ Guidance for Importing Prescription Drugs From Canada

  • Post author:PacConAdmin
  • Post published:May 25, 2022
  • Post category:Drug Industry Daily

To help small entities follow its 2020 final rule on importing prescription drugs from Canada, the FDA released a compliance guide yesterday explaining that U.S. importation programs must show “significant…

Continue ReadingFDA Issues ‘Small Entity’ Guidance for Importing Prescription Drugs From Canada

Verrica Draws Second Complete Response Letter for Manufacturing Deficiencies

  • Post author:PacConAdmin
  • Post published:May 25, 2022
  • Post category:Drug Industry Daily

West Chester, Pa.-based Verrica Pharmaceuticals drew a second Complete Response Letter (CRL) from the FDA rejecting the company’s New Drug Application (NDA) for its investigational drug VP-102 to treat patients…

Continue ReadingVerrica Draws Second Complete Response Letter for Manufacturing Deficiencies

Blockbusters, Accelerated Approval Drugs Get Most FDA-Cleared Formulations

  • Post author:PacConAdmin
  • Post published:May 25, 2022
  • Post category:Drug Industry Daily

Best-selling medicines and drugs cleared under an FDA accelerated approval nab the most FDA-approved new formulations, and this translates to more costs for insurance plans and patients, according to an…

Continue ReadingBlockbusters, Accelerated Approval Drugs Get Most FDA-Cleared Formulations

Nirogacestat, SpringWorks’ Gamma Secretase Inhibitor, Scores in Phase 3 Desmoid Tumor Trial

  • Post author:PacConAdmin
  • Post published:May 25, 2022
  • Post category:Drug Industry Daily

SpringWorks unveiled some good news this week with positive topline data supporting its investigational antitumor drug nirogacestat in patients with progressing desmoid tumors. Source: Drug Industry Daily

Continue ReadingNirogacestat, SpringWorks’ Gamma Secretase Inhibitor, Scores in Phase 3 Desmoid Tumor Trial

Federal Judge Rules Against Gilead in Lexiscan Generic Case

  • Post author:PacConAdmin
  • Post published:May 24, 2022
  • Post category:Drug Industry Daily

A federal judge in Delaware has ended an attempt by Gilead Sciences to defend its Lexiscan (regadenoson) cardiac stress agent from generic competition. Source: Drug Industry Daily

Continue ReadingFederal Judge Rules Against Gilead in Lexiscan Generic Case

Vanda Sues FDA for ‘Capricious’ Denial of Fast-Track Status

  • Post author:PacConAdmin
  • Post published:May 24, 2022
  • Post category:Drug Industry Daily

In an unusual legal action, Vanda Pharmaceuticals is suing the FDA in a federal court for denying a request for Fast-Track designation for its investigational drug tradipitant after a series…

Continue ReadingVanda Sues FDA for ‘Capricious’ Denial of Fast-Track Status

FDA Draft Guidance Gives More Direction for Developing Antibacterial Drugs for Unmet Needs

  • Post author:PacConAdmin
  • Post published:May 24, 2022
  • Post category:Drug Industry Daily

The FDA updates recommendations for drug development programs and clinical trial designs for antibacterial therapies in a revised draft guidance released yesterday. Source: Drug Industry Daily

Continue ReadingFDA Draft Guidance Gives More Direction for Developing Antibacterial Drugs for Unmet Needs
  • Go to the previous page
  • 1
  • …
  • 251
  • 252
  • 253
  • 254
  • 255
  • 256
  • 257
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.